About Vakzine Projekt Management
VPM offers tailor-made consultancy and services based on in-depth experience in development of biopharmaceutical candidates. As a client, you will benefit from the experience of our team in translational project management. This enables you to bring your development projects into clinical trials faster, more cost-effectively and with a higher probability of success.
The company was established in 2002. Within the last decade, VPM has successfully managed and consulted the development of promising biopharmaceutical candidates, ranging from small molecules, recombinant proteins up to gene-modified live vaccines and ATMPs. VPM brought these products for its customers in the pharmaceutical industry, academic research and small biotechnology companies, from preclinical phase through clinical phases I-III.More about us
News & Press
We are pleased to announce that all clinical trial centers, located in Kenya, Tanzania, Uganda, South Africa and Gabon, have started their recruitment and are actively enrolling participants into the pivotal phase III trial (priMe) of the novel tuberculosis vaccine VPM1002.
We thank all consortium partners for the effort in achieving this milestone!
Memo Therapeutics AG Antibodies Against SARS-CoV-2 Show Efficacy Against British and South African Variant
Vakzine Projekt Management supports Memo Therapeutics AG in the clinical development of MTX-COVAB, human-derived antibody against SARS-CoV-2 which has shown excellent neutralizing efficacy against both the original virus as well as the UK variant. Read more!
COVIVAXX is a new vaccine candidate to protect against COVID-19. Developed by the Serum Institute of India Pvt. LTD (SIIPL), the globally leading vaccine manufacturer, VPM coordinates the clinical development in Europe. A phase I/II trial is currently ongoing in Australia to assess the safety and immunogenicity of COVIVAXX in humans. A pivotal phase III trial is planned to be conducted in Europe and India in the first half of 2021. Click here to read more.